Jamshidi, Ahmadreza
Vojdanian, Mahdi
Soroush, Mohsen
Akbarian, Mahmoud
Aghaei, Mehrdad
Hajiabbasi, Asghar
Mirfeizi, Zahra
Khabbazi, Alireza
Alishiri, Gholamhosein
Haghighi, Anousheh
Salimzadeh, Ahmad
Karimzadeh, Hadi
Shirani, Fatemeh
Fard, Mohammad Reza Hatef
Nazarinia, MohammadAli
Soroosh, Soosan
Anjidani, Nassim
Gharibdoost, Farhad
Funding for this research was provided by:
Aryogen Pharmed Company (702806)
Article History
Received: 11 April 2022
Accepted: 15 June 2022
First Online: 30 June 2022
Declarations
:
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the ethics committees of Tehran University of Medical Sciences (No. IR.TUMS.VCR.REC.1395.1588) and Tabriz University of Medical Sciences (No. IR.TBZMED.REC.1395.758). Written informed consent was obtained from each individual participant involved in the study.
: Not applicable.
: Nassim Anjidani is the head of the medical department of Orchid Pharmed Company, which is in collaboration with AryoGen Pharmed Company with respect to conducting clinical trials. There are no other potential conflicts of interest pertaining to this article.